Acne Vulgaris
📧 Sign up to get email alerts when something new happens for Acne Vulgaris.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-12-09FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2020-12-09FDA Approved: ISOTRETINOIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for isotretinoin by Amneal Pharmaceuticals NY LLC. This action approves a change to the approved…
-
FDA approval · 2020-12-09FDA Approved: ABSORICA LD — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for ABSORICA LD (isotretinoin) by Sun Pharmaceutical Industries, Inc., typically related to labeling…
-
FDA approval · 2020-12-09FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLARAVIS (isotretinoin) by Teva Pharmaceuticals USA, Inc., expanding or updating its labeling un…
-
FDA approval · 2020-12-09FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for AMNESTEEM (isotretinoin) from Mylan Pharmaceuticals Inc., indicating an updated approval rel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-12-09FDA Approved: ISOTRETINOIN — Supplemental Application (Mayne Pharma)
The FDA approved a supplemental application for isotretinoin from Mayne Pharma.
-
FDA label_change · 2020-12-09FDA Approved: ABSORICA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ABSORICA (isotretinoin) submitted by Sun Pharmaceutical Industries, Inc., leading to changes…
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne [Phase 3]
Phase 3 trial completed evaluating topical FMX-101 for moderate-to-severe acne; results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-20Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) [Phase 3]
Phase 3 clinical trial evaluating the safety and efficacy of CB-03-01 cream 1% for facial acne vulgaris has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-20Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) [Phase 3]
Phase 3 study of CB-03-01 1% cream for facial acne vulgaris completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris [Phase 3]
Open-label long-term extension evaluating the safety of CB-03-01 cream 1% in acne vulgaris; completed Phase 3 trial with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris [Phase 2]
Phase 2 trial evaluating CB-03-01 cream for acne vulgaris, focusing on adrenal suppression potential and pharmacokinetics.
-
FDA approval · 2020-11-16FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for ZENATANE (isotretinoin) by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris [Phase 3]
Phase 3 trial comparing two treatments for acne vulgaris has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris [Phase 2]
Phase 2 dose-escalation trial assessing safety and efficacy of CB-03-01 cream in facial acne vulgaris has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris [Phase 2]
Phase 2 clinical trial assessing adrenal suppression potential and pharmacokinetics of CB-03-01 cream in pediatric acne vulgaris; study comp…
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris [NA]
Clinical trial update for Venus Versa Diamondpolar and AC dual applicator treatment in facial acne vulgaris; study terminated with results p…
-
CLINICAL_TRIALS trial_result · 2020-10-05Clinical Trial Update: Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris [Phase 3]
Phase 3 bioequivalence study of clindamycin gel 1% for acne vulgaris completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris [Phase 2]
Phase 2 trial update evaluating safety and efficacy of IDP-123 Lotion compared with Tazorac Cream for acne vulgaris.
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne [Phase 3]
Phase 3 trial evaluating topical FMX-101 for moderate-to-severe acne (Acne Vulgaris) has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel [Phase 3]
Phase 3 trial comparing clindamycin phosphate 1.2% / benzoyl peroxide 5% gel to DUAC gel in acne vulgaris; study completed with results post…
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris [Phase 2]
Phase 2 bioavailability study comparing DFD-03 with Tazorac in moderate acne vulgaris completed with results posted.
-
FDA approval · 2020-08-26FDA Approved: WINLEVI — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved WINLEVI (clascoterone) cream for the treatment of acne vulgaris in patients 12 years and older. The drug represents a first-in-…
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris [Phase 2]
Phase 2 study comparing DFD-03 (tazarotene) 0.1% lotion to Tazorac 0.1% cream for acne vulgaris completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-08-03Clinical Trial Update: A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne [Phase 1]
Phase 1 trial update on NB01 for acne vulgaris focusing on safety, engraftment, and action in adults; study completed with results posted.